Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors

Pridgeon, Matthew G.; Grohar, Patrick J.; Steensma, Matthew R.; Williams, Bart O.

doi:10.1007/s11914-017-0377-9

Cited by 38 publications

(29 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The functional role of the Wnt signaling pathway in OS is not completely understood ( 23 ). A number of studies support the idea that the Wnt signaling pathway serves an anti-tumorigenic effect in OS ( 24 – 26 ), whereas other studies suggest that aberrant activation of the canonical Wnt signaling pathway serves an important role in OS initiation, maintenance and resistance to chemotherapy ( 27 , 28 ). In addition, a large number of studies have demonstrated that miRNA has an effect on the development of OS by targeting the Wnt signaling pathway.…”

Section: Discussionmentioning

confidence: 99%

MicroRNA‑1236‑3p inhibits human osteosarcoma growth

Chen

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

Osteosarcoma (OS) is a common bone tumor with high mortality worldwide. The long-term survival rate of patients with metastatic or recurrent disease is <20%. The present study explored the biological role of microRNA (miRNA/miR)-1236-3p in OS. miRNA and mRNA expression levels were measured via reverse transcription-quantitative PCR. Fluorescence in situ hybridization was performed to determine miR-1236-3p expression levels in clinical specimens. Protein expression was measured via western blotting. Immunohistochemical analysis was used to detect Wnt target gene expression in tumor tissues. The interaction between the Wnt3a 3′untranslated region and miR-1236-3p was assessed via dual-luciferase reporter assays. Cell cycle, Transwell, Cell Counting Kit-8 and wound healing assays were conducted to evaluate the function of the miR-1236-3p/Wnt3a axis. Human OS (HOS) cells stably transfected with vector or miR-1236-3p sponge were injected subcutaneously into nude mice to assess the role of miR-1236-3p in vivo . miR-1236-3p expression was downregulated in OS tissues compared with chondroma tissues, and miR-1236-3p overexpression inhibited OS cell migration and proliferation compared with the negative control group. Furthermore, in vivo xenograft assays displayed enhanced tumour growth rates in the miR-1236-3p sponge group compared with the vector control group. In the present study, the results indicated that miR-1236-3p inhibited OS progression and Wnt3a was identified as a target of miR-1236-3p.

show abstract

Section: Discussionmentioning

confidence: 99%

MicroRNA‑1236‑3p inhibits human osteosarcoma growth

Chen

et al. 2020

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…lncRNA PDIA3P activates the Wnt/β-catenin signaling pathway. To determine the underlying mechanism by which PDIA3P affects NSCLC progression, RT-qPCR and western blotting were performed to examine the effects of PDIA3P on the Wnt/β-catenin pathway, which is frequently aberrantly activated in human cancer (19). The results showed that PDIA3P inhibition decreased both the mRNA and protein expression levels of β-catenin and c-myc, and increased the expression levels of GSK-3β in A549 cells ( Fig.…”

Section: Resultsmentioning

confidence: 98%

lncRNA PDIA3P regulates cell proliferation and invasion in non‑small cell lung cancer

Yang

2019

Exp Ther Med

View full text Add to dashboard Cite

Increasing evidence has shown that long non-coding RNAs (lncRNAs) serve a critical role in tumor progression. The lncRNA protein disulfide isomerase family A member 3 pseudogene 1 (PDIA3P) is associated with the progression of oral squamous cell carcinoma and multiple myeloma. However, the roles of lncRNA PDIA3P in non-small cell lung cancer (NSCLC) remain unknown. In the present study, it was demonstrated that lncRNA PDIAP3 expression was significantly increased in patients with NSCLC, particularly in patients with an advanced Tumor-Node-Metastasis stages and lymph-node metastasis. The Gene Expression Profiling Interactive Analysis database revealed that patients with NSCLC with high lncRNA PDIA3P expression had a poorer disease-free survival rate. Furthermore, functional assays suggested that PDIA3P inhibition significantly suppressed the proliferation and invasion of NSCLC cells in vitro and reduced tumor growth in vivo. In addition, lncRNA PDIA3P enhanced the activity of the Wnt/β-catenin pathway in progression of NSCLC. The present study showed that lncRNA PDIA3P promoted NSCLC progression by regulating Wnt/β-catenin signaling, highlighting a potential therapeutic target for treating patients with NSCLC treatment.

show abstract

“…As a bone‐forming agent and activator of the canonical osteoanabolic Wnt‐signalling pathway, a potential for carcinogenesis has been raised with romosozumab. The WNT‐signalling pathway has been related to different human cancers . In human osteosarcoma tissue, the presence of Wnt receptor LRP5 correlates with a worse prognosis .…”

Section: Dual Actions Drug: Romosozumabmentioning

confidence: 99%

Osteoanabolic and dual action drugs

Tabacco

Bilezikian

2019

Brit J Clinical Pharma

View full text Add to dashboard Cite

Teriparatide (TPTD) and Abaloparatide (ABL) are the only osteoanabolic drugs available, at this time, for treatment of osteoporosis. TPTD is a 34-amino acid fragment that is identical in its primary sequence to the 34 amino acids of full-length human parathyroid hormone [hPTH(1-84)]. ABL is identical to parathyroid hormone related peptide (PTHrP) through the first 22 residues with significantly different amino acids inserted thereafter, between residues 22 and 34. The osteoanabolic actions of PTH are due directly to its effects on cells of the osteoblast lineage and indirectly by stimulating IGF-I synthesis and suppressing sclerostin and associated enhancement of Wnt signaling. Both TPTD and ABL are ligands that bind to and activate the PTH receptor type 1 (PTHR1) receptor but they appear to do so differently: ABL favors the transient, more anabolic configuration of the receptor. Both TPTD and ABL reduce the risk of vertebral fractures and non-vertebral fractures. Both drugs are administered for a maximum of 24 months, and should be followed by an anti-resorptive agent to maintain gains in BMD. Romosozumab, a monoclonal antibody that binds to and inhibits sclerostin, appears to have dual actions by stimulating bone formation and reducing bone resorption. In the pivotal clinical trial, romosozumab, administered as a 210 mg monthly subcutaneous dose, significantly reduced new vertebral fractures and in a subsequent study reduced both vertebral and non-vertebral fractures.

show abstract

Wnt Signaling in Ewing Sarcoma, Osteosarcoma, and Malignant Peripheral Nerve Sheath Tumors

Cited by 38 publications

References 88 publications

MicroRNA‑1236‑3p inhibits human osteosarcoma growth

MicroRNA‑1236‑3p inhibits human osteosarcoma growth

lncRNA PDIA3P regulates cell proliferation and invasion in non‑small cell lung cancer

Osteoanabolic and dual action drugs

Contact Info

Product

Resources

About